INTRODUCTION
Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler-Scheinker syndrome (GSS) are etiologically related but phenotypically dissimilar neurologic disorders. GSS is characterized by slowly progressive ataxia, parkinsonism, and dementia beginning in the third through seventh decades and progresses to death over 2 to 10 years (Gerstmann et al., 1936; Masters et al., 1981) . CJ D is characterized by rapidly progressive dementia later associated with a variety of other neurologic signs including jerking of the extremities (myoclonus), muscle twitching (fasciculations), spasticity, and blindness (Kirschbaum, 1968; Roos et al., 1973; Brown and Gajdusek, 1991) Neuropathologic features of these conditions include loss and degeneration of neurons, gliosis, spongiform appearance of gray matter, and variable deposition of extracellular amyloid (Beck and Daniel, 1987) . These amyloid deposits contain large amounts of prion protein (PrP) encoded by the PrP gene on chromosome 20 (Kitamoto et al., 1986; Sparkes et al., 1986) . GSS is uniformly transmitted through autosomal dominant inheritance (Masters et al., 1981; . In contrast, the majority of CJD patients have a sporadic condition with only 5 to 15% of CJD patients acquiring the 0 1994 WILEY-LISS, INC. disorder through autosornal dominant inheritance Masters et al., 1979) . Iatrogenic CJD is transmissible through organ transplants and pharmaceutical preparations containing material derived from CJD or GSS patients (Duffy et al., 1974; Tinter ct al., 1986) . There is compelling evidence that the transmissible agent or prion is composed largely, if not entirely, of an abnormal form of PrP designated PrP"' (Prusiner, 1982 (Prusiner, , 1987 .
PrP coding sequence mutations are present in GSS patients and familial CJD patients (Fig. 1A ) Hsiao et al., 1989; Doh-ura et al., 1989; Fink et al., 1991; Nieto et al., 1991; Dhouhy et al., 1992; Hsiao et al., 1992; Goldgaber et al., 1989) . These mutations are associated specifically with these disorders and the rare condition, fatal familial insomnia (FFI) (Lugaresi et al., 1991; Medori et al., 1991) . When tested, these mutations have shown genetic linkage with these disorders PCR primers and reaction conditions are given in Table 1. (C) Melt87 analysis of PrP amplification fragments A (-.) and B (-).
et al. , 1992) . PrP mutation at codon 10ZLe" was shown to be directly pathogenic when its expression produced an inherited neurodegenerative disorder in transgenic mice . In general, PrP mutations associated with the syndrome of familial CJD are different from those associated with GSS (Goldfarb et al., 1990) . Point mutations in PrP codons 102LeL ', 117""', 198' ", and 21 7Arg are associated with GSS. An additional point mutation at codon 105LeL' was recently identified in GSS patients with spastic paraparesis (Kitamoto et al., 1993) . PrP mutations associated with familial CJD include insertions of varying numbers of a 24-base pair repeat (144 nucleotides, for example) between codons 51 and 92 and point mutations in codons 178A'p and 20OLyS. In addition to these diseasespecific mutations, benign PrP polymorphisms have been found in normal subjects, including point mutations in codons 124 (Hsiao et al., 1992) and 117 and a 24-base pair deletion (VnencakJones et al., 1992; Laplanche et al., 1990) .
The polymorphism at PrP codon 129 may be clinically significant. The greatly increased frequency of homozygosity at codon 129 among sporadic CJD patients (approximately 90%) compared to normal subjects (63%) raises the possibility that this codon may contribute to the development of developing sporadic CJD (Palmer et al., 1991) . Furthermore, the codon 129 genotype may affect the age of onset of familial CJD or GSS patients (Baker et al., 1991; Dhouhy et al., 1992) or whether patients exhibit the CJD phenotype or FFI phenotype (Goldfarb et al., 1992) .
Observations of PrP mutations in GSS patients with absent or atypical (Collinge et al., 1990; Dhouhy et al., 1992; Hsiao et al., 1992) (Fischer and Lerman, 1983) and allelespecific DNA sequencing to identify a novel PrP mutation (Fink et al., 1991) in a familial CJD patient. This approach has been extended to allow mutations in other regions of the PrP coding sequence to be detected. We show that this technique readily identifies known PrP point mutations. In addition, this method facilitates detection of novel PrP mutations in samples from many patients. We illustrate the sensitivity of this approach by reporting two novel polymorphisms of the PrP coding sequence.
MATERIALS AND METHODS Patients and DNA Samples
Genomic DNA samples were obtained from CJD and GSS patients for whom PrP mutations had been identified by restriction enzyme and DNA sequence analysis. The exceptions were the normal subject for whom the codon 129v"'/129v"', codon l2gMetlMet , and codon 1 29Mrt/Val genotypes were demonstrated by Nspl restriction enzyme analysis (data not shown).
Computer Analysis
The MELT87 
PrP Amplification
The PrP coding sequence was amplified as overlapping fragments (Fig. 1B ) from genomic DNA extracted from leukocytes. The only exceptions were DNA samples containing codon 1 17A'" and 1 17v"' for which the PrP alleles cloned into bacterial plasmids served as the PCR template. PCR primers and amplification parameters are given in Table 1 . Nucleotide positions are numbered according to Kretzschmar et al. (1986) .
Denaturing Gradient Gel Electrophoresis
Following amplification, PrP fragments were denatured by heating to 95°C for 10 min. Reannealing was carried out at 80°C for 2.5 min followed by 42°C for 5 min. 5 ml of loading buffer (40% glycerol, 0.1% bromphenol blue) were added to the 50 ml PCR product. Aliquots (20-25 pl) of this mixture were electrophoresed on denaturing gradient polyacrylamide gels as specified in Table 1 . Mutant and normal PrP amplified from plasmid templates were mixed (1:l) prior to denaturation and reannealing in order to mimic the situation of amplifying genomic DNA from a patient who was heterozygous at codon 1 1 7v"'/1 1 7A'a. 
Restriction Enzyme Analysis

RESULTS
We used the MELTS7 computer program (Lerman 1990) (Fig. 1C) to design a strategy in which regions of the PrP coding sequence known to have point mutations would be in the lowest melting domain of an amplification fragment. Figure 2A and B show that known PrP point mutations are readily detectable by DGGE.
The sensitivity of this approach suggested that novel mutations in these regions would be readily detected. This prediction was confirmed by finding unique DGGE polymorphisms in a control subject and in a patient with Alzheimer's disease (AD) (Fig. 3A) . The control subject was a male who died at age 69 and had no evidence of AD or spongiform degeneration at postmortem examination. Direct DNA sequencing revealed substitution of guanine (for adenine) at nucleotide 561 in the control subject. This polymorphism creates a Bst71I site (Fig. 3B ) and predicts substitution of serine for asparagine at codon 171 (AAC -+ AGC). Whether the codon 171' " -+ Asp is a rare but benign variant or potentially pathogenic is not known. Direct DNA sequencing of the AD patient's sample revealed substitution of adenine for guanine at nucleotide 532. This polymorphism creates an AccI site, deletes an RsaI site (Fig. 3B) , and does not change the valine at codon 161 (GTG -+ GTA).
In addition to detecting known and novel PrP mutations, when used in conjunction with restriction enzyme analysis, our method often can determine PrP haplotypes. Determination of PrP haplotypes by DGGE is particularly useful in cases where the mutation either does not change a re- and heterozygous for a benign polymorphism at codon 129Met'Va' (lane 5); a normal subject heterozygous for a benign polymorphism at codon 129Md'Va' (lane 6); a normal subject with a 24 base pair deletion who was also hetsample in lane 4, this subject also has the pathogenic codon 11 7"CA mutation on the same allele containing the benign change at codon 129vd'. In contrast to the downward displacement of I 17GC", 129v"' (compared with 1 17CITA, 129v"'), the double nucleotide substitution causes negligible displacement of the homoduplex since the two substitutions have opposing affects on melting temperature (C -+ T and A -+ G). Note, however, the separation of homoduplexes from heteroduplexes. Compared to homoduplexes, the heteroduplexes have greatly reduced melting temperature because of the 2-base pair mismatch that forms when these mutant and normal alleles reanneal ( Fig. 2A, lanes 4 and 5) .
As expected, the largest separation of homoand heteroduplexes occurred in samples with the 24-base pair deletion ( Fig. 2A, lanes 8 and 9) .
Since this deletion occurs in the octapeptide repeat region, heteroduplexes may form in 2 ways.
The deletion creates a 24-base pair mismatch that may be placed either internally (creating a 24-base pair loop) or at the 5' end (creating staggered ends and a terminal region of nonhomology). Owing to slight variations in this repeat region, however, this latter structure creates 3 separate single-nucle- Control samples in lanes 1 and 2 are PrP (fragment B) amplified from a normal subject homozygous at codon 129M"' Met (lane 1) and a familial CJD patient heterozygous for a benign polymorphism at codon 129Ma'Va1 and heterozygous for a pathogenic mutation at codon 178ASp'As" (lane 2). Samples with novel DGGE polymorphisms (lanes 3 and 4) are from an Alzheimer's patient homozygous at codon 129M"'Me'
and heterozygous for a benign nucleotide polymorphism at codon 161GTGGTA (Val-Val) (lane 3); and a control subject homozygous at codon 129va"va1 and heterozygous at codon otide mismatches (at nucleotides 277, 295, and 301). We feel that this latter heteroduplex with staggered 5 ' ends and 3 separate single-nucleotide mismatches best explains the large difference in melting profiles (and resulting gel separation) between hetero-and homoduplex species with the 24-base pair deletion.
DISCUSSION
DGGE is an extremely sensitive and efficient method for screening large numbers of samples for single nucleotide substitutions, small insertions, and deletions. Principles of mutation detection by DGGE are reviewed elsewhere (Meyers et al., 1987) . Known PrP point mutations (reviewed in Palmer and Collinge, 1993) (Riesner et al., 1992) or single-strand conformation analysis (Orita et al., 1989) A PrP insertional mutation was found in a patient with familial ataxia and dementia characteristic of GSS in whom there was no evidence of spongiform degeneration (Collinge et al., 1990; Poulter et al., 1992) . Amyloid deposits in this patient were evident only with immunohistochemical staining . Furthermore, mutations in PrP codons 198' " and 217A'g were present in patients with dominantly inherited dementia, ataxia, and parkinsonism whose postmortem findings of senile plaques and neurofibrillary tangles were similar in appearance (but not distribution) to Alzheimer's disease in contrast to spongiform degeneration characteristic of GSS and CJD (Dhouhy et al., 1992; Hsiao et al., 1992) .
Using the parameters of disease transmissibility (Brown et al., 1993) and immunologic detection of PrP (Brown et al., 1993; Kitamoto et al., 1992) , Brown ( 1993) (Feldman et al., 1963; Hansen et al., 1990 
